{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:21:43Z","timestamp":1783444903140,"version":"3.54.6"},"reference-count":22,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":1979,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction: Lenvatinib (LEN) is a multitarget tyrosine kinase inhibitor currently used for advanced, radioiodine refractory differentiated thyroid cancer (RAI-R DTC). Among adverse events (AEs), nausea, vomiting, and decreased appetite have been frequently described. We aimed to evaluate the prevalence, the clinical presentation, and the effectiveness of conservative treatment of gallbladder disorders in a consecutive series of patient treated with LEN. Methods: Patients with RAI-R DTC experiencing clinical symptoms suggestive for gallbladder disorders during LEN treatment were evaluated with laboratory investigations and contrast-enhanced abdominal computed tomography (CT) and ultrasound scan (US). Results: After a median time of 2 months from the start of treatment, 5\/13 patients (38.4%) complained of gastrointestinal symptoms, with increased biliary enzymes levels, especially \u03b3GT, and CT\/US suggestive of acute cholecystitis (AC). The onset of symptoms and the peak of \u03b3GT levels frequently corresponded to the highest reduction in body weight during the first months of treatment. All patients were treated with supportive care and, when appropriate, with ursodeoxycholic acid; in 4 patients, LEN dose reduction or short interruption was needed, too. Conclusions: In patients with RAI-R DTC treated with LEN, a high prevalence of AC in the first months of treatment was documented. Mainly due to the low specificity of symptoms such as anorexia, nausea, and vomiting, this AE is likely to be frequently misdiagnosed. The onset of the disease was associated to the weight loss observed during the first months of treatment and contributes to further decrease in body weight. Therefore, particularly during the first months of treatment, or at any time of huge reduction of body weight, monitoring of \u03b3GT and US is crucial for prompt diagnosis and treatment. Conservative medical treatment and LEN dosage titration, together with dietary and rehabilitative supports, can limit or avoid the need for drug withdrawal and cholecystectomy.<\/jats:p>","DOI":"10.1159\/000510369","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T17:00:28Z","timestamp":1600275628000},"page":"314-322","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":11,"title":["High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer"],"prefix":"10.1530","volume":"10","author":[{"given":"Marta","family":"Di Stefano","sequence":"first","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Perrino","sequence":"additional","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[{"name":"3Division of Hepatology, San Giuseppe Hospital Multimedica IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2068-9581","authenticated-orcid":false,"given":"Luca","family":"Persani","sequence":"additional","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"},{"name":"4Department of Clinical Sciences and Community Health, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[{"name":"1Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"issue":"7","key":"2026070711520409100_ref1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10126","key":"2026070711520409100_ref2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018  24","journal-title":"Lancet"},{"issue":"5","key":"2026070711520409100_ref3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"issue":"3","key":"2026070711520409100_ref4","first-page":"1643","article-title":"Lenvatinib in advanced radioiodine-refractory thyroid cancer: a snapshot of real-life clinical practice","volume":"38","author":"Nervo","year":"2018","journal-title":"Anticancer Res"},{"key":"2026070711520409100_ref5","article-title":"Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice","author":"Berdelou","year":"2017  27","journal-title":"Thyroid"},{"issue":"2","key":"2026070711520409100_ref6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12020-017-1499-7","article-title":"Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice","volume":"59","author":"Molina-Vega","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"2026070711520409100_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000504048","article-title":"Body composition and leptin\/ghrelin levels during lenvatinib for thyroid cancer","volume":"9","author":"De Leo","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2026070711520409100_ref8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/thy.2019.0355","article-title":"Symptomatic biliary disorders during lenvatinib treatment for thyroid cancer: an underestimated problem","volume":"30","author":"Nervo","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"2026070711520409100_ref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026070711520409100_ref10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00423-006-0103-z","article-title":"Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment","volume":"391","author":"Yeh","year":"2006","journal-title":"Langenbecks Arch Surg"},{"issue":"23","key":"2026070711520409100_ref11","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026070711520409100_ref12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2026070711520409100_ref13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clinimag.2013.08.012","article-title":"Gallbladder complications associated with molecular targeted therapies: clinical and imaging features","volume":"38","author":"Tirumani","year":"2014","journal-title":"Clin Imaging"},{"issue":"1","key":"2026070711520409100_ref14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CGC.2009.n.011","article-title":"Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib","volume":"7","author":"Gomez-Abuin","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"2026070711520409100_ref15","volume-title":"Harrison\u2019s principles of internal medicine","author":"Jameson","year":"2018","edition":"12th ed"},{"issue":"1","key":"2026070711520409100_ref16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cgh.2009.08.034","article-title":"Acute acalculous cholecystitis: a review","volume":"8","author":"Huffman","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2026070711520409100_ref17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026070711520409100_ref18","doi-asserted-by":"crossref","first-page":"201529","DOI":"10.5402\/2011\/201529","article-title":"Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib","volume":"2011","author":"Sanda","year":"2011","journal-title":"ISRN Gastroenterol"},{"issue":"4","key":"2026070711520409100_ref19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2005.12.034","article-title":"Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism","volume":"130","author":"Gaudio","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"2026070711520409100_ref20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2016.03.005","article-title":"EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones","volume":"65","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"2026070711520409100_ref21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0196-0644(96)70024-0","article-title":"Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis","volume":"28","author":"Singer","year":"1996","journal-title":"Ann Emerg Med"},{"issue":"12","key":"2026070711520409100_ref22","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3748\/wjg.v9.i12.2821","article-title":"Clinical predictors of severe gallbladder complications in acute acalculous cholecystitis","volume":"9","author":"Wang","year":"2003","journal-title":"World J Gastroenterol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/4\/314\/21831\/etj510369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/4\/314\/21831\/etj510369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:27:46Z","timestamp":1783441666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/10\/4\/314\/2755\/High-Prevalence-and-Conservative-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000510369","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}